BACKGROUND: An effective vaccine is urgently needed against the H7N9 avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets. METHODS: Ferrets were vaccinated with 2 doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine, and the induction of antibodies to hemagglutinin (HA) or neuraminidase proteins was evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro. RESULTS: Adjuvanted vaccines stimulated robust serum antibody titers against HA and neuraminidase compared with the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 µg of HA), both adjuvants induced comparable antibody responses after 2 doses of 15 µg. On challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies. CONCLUSIONS: The adjuvanted H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold potential as a vaccination regimen.
BACKGROUND: An effective vaccine is urgently needed against the H7N9avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets. METHODS:Ferrets were vaccinated with 2 doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine, and the induction of antibodies to hemagglutinin (HA) or neuraminidase proteins was evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro. RESULTS: Adjuvanted vaccines stimulated robust serum antibody titers against HA and neuraminidase compared with the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 µg of HA), both adjuvants induced comparable antibody responses after 2 doses of 15 µg. On challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies. CONCLUSIONS: The adjuvanted H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9infection in ferrets and hold potential as a vaccination regimen.
Authors: Aleksandr S Lipatov; Erich Hoffmann; Rachelle Salomon; Hui-Ling Yen; Robert G Webster Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Rebecca J Cox; Abdullah S Madhun; Solveig Hauge; Haakon Sjursen; Diane Major; Mirjam Kuhne; Katja Höschler; Melanie Saville; Frederick R Vogel; Wendy Barclay; Isabella Donatelli; Maria Zambon; John Wood; Lars R Haaheim Journal: Vaccine Date: 2009-02-02 Impact factor: 3.641
Authors: Hans C Rümke; Jan Hendrik Richardus; Lars Rombo; Karlis Pauksens; Georg Plaßmann; Christelle Durand; Jeanne-Marie Devaster; Walthère Dewé; Lidia Oostvogels Journal: BMC Infect Dis Date: 2013-07-26 Impact factor: 3.090
Authors: Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes Journal: NPJ Vaccines Date: 2020-05-11 Impact factor: 7.344
Authors: Li Wang; Timothy Z Chang; Yuan He; Jong R Kim; Shelly Wang; Teena Mohan; Zachary Berman; S Mark Tompkins; Ralph A Tripp; Richard W Compans; Julie A Champion; Bao-Zhong Wang Journal: Nanomedicine Date: 2016-09-10 Impact factor: 5.307
Authors: Wenlan Alex Chen; Jinjin Zhang; Katie M Hall; Carol B Martin; Serguei Kisselev; Emily J Dasen; Nicholas N Vahanian; Charles J Link; Brian K Martin Journal: PLoS One Date: 2017-08-07 Impact factor: 3.240